Pfizer COVID-19 vaccine candidate tapped by HHS for large-scale production
The Department of Health and Humans Services today said it has an agreement with Pfizer to produce and deliver 100 million doses of the drug maker’s COVID-19 vaccine candidate.
The agreement, which also includes the Department of Defense and is contingent on the vaccine’s successful manufacture and approval, allows the U.S. government to acquire an additional 500 million doses, provided that the Food and Drug Administration issues an emergency use authorization or licensure for safety and efficacy in a large Phase 3 clinical trial.
Related News Articles
Headline
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…
Headline
The Centers for Disease Control and Prevention's COVID-19 data tracker shows an 18.1% test positivity rate for the week ending Aug. 10, the highest it has been…
Headline
The Centers for Disease Control and Prevention Aug. 13 issued an advisory alerting of an uptick of cases of parvovirus B19 across the U.S. Parvovirus B19 is a…
Blog
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…